Resilience, 908 Devices Demonstrate Lower Cost of Perfusion Bioreactor Process

908 Devices Inc., a provider of purpose-built handheld and desktop devices for chemical and biochemical analysis, reported that National Resilience, Inc., a technology-focused biomanufacturing company, has adopted REBEL at-line media analyzers in their process development to inform and optimize cell culture feed strategies and media design.

According to the company, REBEL provides insights into cell metabolism to enable Resilience process engineers to measure spent media samples to monitor amino acid depletion during a monoclonal antibody perfusion process. Resilience demonstrated, using REBEL, a 50% increase in titer while reducing cost of goods by adding back only the nutrients the cells have depleted.

“Data from the REBEL enables our teams to improve the speed of development, allowing for rapid optimization of our media feeds,” said Andy Grube, director of upstream process development, biologics franchise at Resilience. “Cell culture media and feed costs are significant in a perfusion process. With at-line media analysis, we can optimize and accelerate biotherapeutic development, with the ultimate goal of reducing cost of goods and time to submission.”

In a statement, the company said that Resilience engineers are researching various techniques to lower the cost of media used in a perfusion process. At-line media analysis enables process development engineers to make decisions throughout the bioreactor run and inform feeding models, thereby improving cell culture outcomes and maximizing bioreactor utilization.